Trials / Completed
CompletedNCT00976118
Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adults Patients With Mild to Moderate Alzheimer-type Disease.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- AB Science · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This phase 2 study was designed to evaluate the activity of oral masitinib (AB1010) administered at 2 dose levels during 24 weeks to patients with mild to moderate confirmed Alzheimer's type disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | masitinib (AB1010) | oral masitinib 3 or 6 mg/kg/day |
| DRUG | placebo | matching placebo to masitinib |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2008-07-01
- Completion
- 2009-02-01
- First posted
- 2009-09-14
- Last updated
- 2018-12-13
Source: ClinicalTrials.gov record NCT00976118. Inclusion in this directory is not an endorsement.